Metronomic Capecitabine in Stage III Gastric Cancer - Trial NCT06313567
Access comprehensive clinical trial information for NCT06313567 through Pure Global AI's free database. This Phase 3 trial is sponsored by Fudan University and is currently Recruiting. The study focuses on Gastric Cancer. Target enrollment is 722 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Fudan University
Timeline & Enrollment
Phase 3
Mar 10, 2024
Mar 10, 2029
Primary Outcome
Disease-free survival
Summary
The purpose of this study is to find out whether treatment with metronomic capecitabine will
 improve the survival of gastric cancer patients with stage III who had received standard
 treatment.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06313567
Non-Device Trial